SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.05-0.6%Dec 9 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who started this subject2/28/2001 8:52:34 AM
From: blue_chip   of 52153
 
Oncolytics Biotech Inc. Announces Results of REOLYSIN(R)
Treatment of Metastatic Cancer in Animal Models

CALGARY, ALBERTA--Oncolytics Biotech Inc. (TSE:ONC) reported today
that Dr. Patrick Lee and his research group at the University of
Calgary will present the results of their work with REOLYSIN(R)
for the treatment of metastatic cancer in animal models. The
results will be presented at the AACR (American Association of
Cancer Research) meeting in New Orleans in March 26, 2001, with
the abstract being released today.

Dr. Lee and his colleagues were able to demonstrate, in an immune
competent mouse model, that REOLYSIN(R) administered intravenously
(IV) led to a significant reduction in tumour volume. Co-therapy
with cyclosporine or cisplatin further reduced tumour size. In a
Lewis lung carcinoma mouse model they demonstrated that IV
treatment with REOLYSIN(R) also resulted in a significant
reduction in tumour volume. In a systemic metastatic immune
competent mouse model, they demonstrated that IV treatment with
REOLYSIN(R) resulted in a significant enhancement of survival rate
in these animals.

"These results are an exciting indication that REOLYSIN(R) can be
administered systemically in animals with an immune system for the
treatment of both solid tumours and metastatic disease. This is
very important as the majority of cancers have some metastatic
involvement," said Dr. Matt Coffey, Vice President of Product
Development for Oncolytics. "It is also very encouraging to see
experiments being successfully performed using REOLYSIN(R) as a
co-therapy with existing drugs."

More info on ONC at thenextwave.emerchantpro.com

regards
Chip
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News